In this articleMRNAFollow your favorite stocksCREATE FREE ACCOUNTNikos Pekiaridis | Nurphoto | Getty ImagesModerna on Thursday posted a narrower-than-expected loss for the first quarter as the company's cost-cutting efforts took hold and sales of its Covid vaccine, its only commercially available product, topped estimates. The results come as Moderna inches closer to putting another product on the market, which it badly needs as demand for Covid shots plunges worldwide.

在这篇文章中，你最喜欢的stocksCREATE FREE ACCOUNTNikos Pekiaridis | Nurphoto | Getty ImagesModerna周四公布了第一季度的亏损，低于预期，因为该公司的成本削减努力得以实施，其唯一可商购产品新型冠状病毒疫苗的销售超过了预期。随着Moderna距离将另一种产品推向市场的距离越来越近，随着全球对新型冠状病毒疫苗的需求急剧下降，它迫切需要这种产品。

The biotech company expects a U.S. approval for its vaccine against respiratory syncytial virus on May 12. If cleared, that shot is expected to launch in the third quarter.Here's what Moderna reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:Loss per share: $3.07 vs.

这家生物技术公司预计其呼吸道合胞病毒疫苗将于5月12日获得美国批准。如果获得批准，该疫苗有望在第三季度推出。根据伦敦证交所（LSEG）对分析师的调查，Moderna第一季度的报告与华尔街的预期相比如下：每股亏损：3.07美元vs。

loss of $3.58 expectedRevenue: $167 million vs. $97.5 million expectedThe biotech company booked first-quarter sales of $167 million, with revenue from its Covid shot dropping roughly 90% from the same period a year ago. Moderna reported $1.86 billion in revenue in the prior-year period.Around $100 million came from the U.S., while $67 million came from international markets, primarily in Latin America, Moderna CFO Jamey Mock told CNBC in an interview. The company said the revenue decline came in part from an expected transition to a seasonal Covid vaccine market, where patients typically take their shots in the fall and winter.Moderna posted a net loss of $1.18 billion, or $3.07 per share, for the first quarter.

预计亏损358美元：1.67亿美元，而预期亏损9750万美元生物技术公司第一季度销售额为1.67亿美元，新型冠状病毒注射的收入比去年同期下降约90%。Moderna报告称，上一年的收入为18.6亿美元。Moderna首席财务官杰米·莫克（JameyMock）在接受CNBC采访时表示，大约1亿美元来自美国，而6700万美元来自国际市场，主要来自拉丁美洲。该公司表示，收入下降的部分原因是预期将转向季节性新型冠状病毒疫苗市场，患者通常在秋季和冬季接种。Moderna公布第一季度净亏损11.8亿美元，即每股3.07美元。

That compares with net income of $79 million, or 19 cents per share, reported for the year-ago period.The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from its RSV vaccine. Notably, the company expects only $300 mil.

相比之下，去年同期报告的净收入为7900万美元，即每股19美分。该公司重申了2024年全年约40亿美元的销售指导，其中包括其RSV疫苗的收入。值得注意的是，该公司预计只有3亿美元。